Switching to aromatase inhibitor may lower risk of recurrence
A recent study, presented at the prestigious 31st Annual San Antonio Breast Cancer Symposium, has found that women who switched to an aromatase inhibitor (AI) after two to three years of Tamoxifen lowered… Continue reading